Why CRISPR Therapeutics Stock Rocked the Market Last Month
Key PointsThe FDA-approved drug it helped developed saw a nearly 80% sequential rise in sales.
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.